Grifols (GRFS) Cash from Investing Activities Growth (1y) (2011 - 2020)
Grifols (GRFS) Cash from Investing Activities Growth (1y) (2011 - 2020) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Cash from Investing Growth (1y) (Qtr) |
| 1 |
Eli Lilly |
1,066.16 Bn |
1,060.88 Bn |
16.22 Bn |
-16.79% |
| 2 |
Johnson & Johnson |
611.69 Bn |
589.64 Bn |
15.96 Bn |
-250.17% |
| 3 |
AbbVie |
444.34 Bn |
434.99 Bn |
10.78 Bn |
21.90% |
| 4 |
Astrazeneca |
284.94 Bn |
277.05 Bn |
12.61 Bn |
-43.02% |
| 5 |
Merck |
224.23 Bn |
218.58 Bn |
12.09 Bn |
-586.62% |
| 6 |
Amgen |
195.12 Bn |
183.08 Bn |
5.87 Bn |
-60.18% |
| 7 |
Gilead Sciences |
156.45 Bn |
148.73 Bn |
5.52 Bn |
526.51% |
| 8 |
Pfizer |
136.01 Bn |
123.24 Bn |
-1.21 Bn |
-76.02% |
| 9 |
Novartis Ag |
113.45 Bn |
113.67 Bn |
- |
- |
| 10 |
Grifols |
- |
- |
- |
- |
| Date | Value |
|---|
| Mar 31, 2020 |
56.61% |
| Dec 31, 2019 |
-157.70% |
| Mar 31, 2019 |
-340.75% |
| Dec 31, 2018 |
-68.90% |
| Jun 30, 2018 |
-676.00% |
| Mar 31, 2018 |
-93.95% |
| Dec 31, 2017 |
2,116.99% |
| Dec 31, 2016 |
90.81% |
| Sep 30, 2016 |
-1,045.50% |
| Dec 31, 2015 |
-1,326.81% |
| Sep 30, 2015 |
-97.72% |
| Jun 30, 2015 |
127.26% |
| Mar 31, 2015 |
-126.24% |
| Dec 31, 2014 |
10.07% |
| Sep 30, 2014 |
4,410.93% |
| Jun 30, 2014 |
-6,268.57% |
| Mar 31, 2014 |
2,151.36% |
| Dec 31, 2013 |
52.36% |
| Sep 30, 2013 |
368.96% |
| Jun 30, 2013 |
3,273.90% |
